Understanding Good Distribution Practices

What this article covers and who should read it

Good Distribution Practices (GDP) are the regulatory framework governing the wholesale distribution of medicinal products. If you are moving into a distribution role, transitioning from manufacturing QA, preparing for a Responsible Person position, or simply need to understand how medicines are handled after they leave the factory gate, this article covers the fundamentals. It assumes you already work in the pharmaceutical industry and understand basic quality concepts but need a structured orientation to GDP-specific requirements.

What Good Distribution Practices are and why they exist

GDP is the set of standards that ensures medicinal products are consistently stored, transported, and handled under suitable conditions throughout the supply chain, from the manufacturer or importer through to the entity that dispenses or administers the product. The goal is straightforward: the product reaching the patient should be the same product that was released by the Qualified Person at the manufacturing site, uncompromised by poor storage, mishandling, or diversion through illegitimate channels.

Without GDP, a product manufactured under rigorous GMP conditions could degrade in an uncontrolled warehouse, be exposed to temperature excursions during transit, or be substituted with a falsified medicine. GDP closes that gap.

The relationship between GMP and GDP

GMP governs manufacturing, testing, and release. GDP governs what happens next. The handoff typically occurs when the finished product leaves the manufacturing or QP-release site and enters the distribution chain. In practice, many organisations hold both a manufacturing authorisation and a wholesale distribution authorisation, so the boundary can blur. A warehouse operated under a manufacturing licence follows GMP; the same warehouse operating under a wholesale distribution authorisation follows GDP. The quality expectations are analogous (controlled storage, calibrated equipment, trained personnel, deviation management), but the specific regulatory requirements differ.

Both frameworks are necessary because the risks differ. Manufacturing risks centre on process control, contamination, and product consistency. Distribution risks centre on storage integrity, transport conditions, traceability, and the authenticity of products moving between trading partners.

Scope of GDP — which activities and products are covered

GDP covers procurement, receipt, storage, and supply of medicinal products by wholesale distributors. It also covers transportation, whether performed by the distributor directly or outsourced to a logistics provider. The scope extends to active substances where they are subject to GDP requirements (the EU has a separate GDP guideline for this). Brokers, who arrange transactions without physically handling product, are also subject to certain registration and GDP obligations in the EU.

If your organisation purchases medicinal products from manufacturers or other wholesalers, stores them, and sells them on, GDP applies to you.

The regulatory framework underpinning GDP

EU GDP guidelines for medicinal products for human use

The EU operates two principal GDP guidelines. The first, published in 2013, applies to wholesale distributors of medicinal products for human use and is based on Article 84 and Article 85b of Directive 2001/83/EC. It covers quality systems, personnel, premises, documentation, operations, complaints, returns, falsified medicines, self-inspection, and transportation. The second guideline covers GDP for active substances and was also published in 2015, addressing the distribution of APIs intended for medicinal products for human use.

National competent authorities (such as the MHRA in the UK, the HPRA in Ireland, or the BfArM/regional authorities in Germany) enforce these guidelines through inspection and licensing. A wholesale distribution authorisation is required before an entity may legally distribute medicinal products in the EU.

GDP-equivalent frameworks outside the EU

The WHO publishes GDP guidance that many countries outside the EU adopt or adapt. PIC/S also provides a GDP guide used as a benchmark by its member inspectorates. In the United States, distribution requirements are embedded across multiple FDA regulations rather than consolidated into a single GDP guideline, with the Drug Supply Chain Security Act (DSCSA) adding specific serialisation and verification requirements. The principles are broadly consistent worldwide: control storage and transport conditions, verify trading partners, maintain traceability, and operate within a quality system.

Core requirements of Good Distribution Practices

Quality management system and the role of the Responsible Person

Every wholesale distributor must operate a pharmaceutical quality system (PQS). This system governs how the organisation manages quality across all GDP activities: receiving goods, storing them, picking and dispatching orders, handling deviations, processing complaints, and managing recalls.

The Responsible Person is the named individual who ensures GDP compliance. Under EU GDP guidelines, the Responsible Person must have defined responsibilities, appropriate competence, and sufficient authority. Their duties include approving returns to saleable stock, authorising deliveries, approving qualification of suppliers and customers, ensuring training is current, and coordinating self-inspections. Unlike a QP in manufacturing, the Responsible Person does not release individual batches. Instead, they maintain oversight of the entire distribution operation.

Management must provide the Responsible Person with adequate resources. A Responsible Person who exists on an organisational chart but lacks authority or time to fulfil their role is a common inspection finding.

Premises, equipment, and temperature control

Warehouses must be suitable for the products stored in them. This means adequate space, cleanliness, pest control, segregation of rejected or quarantined goods, and security against unauthorised access.

Temperature control is a dominant concern. Most medicinal products require storage below 25°C; many require 2°C to 8°C. Warehouses must be temperature-mapped to identify the warmest and coldest spots under representative seasonal conditions. Monitoring systems must continuously log temperatures with alarms that trigger when conditions drift out of range. Sensors require regular calibration traceable to national standards.

Cold chain management is a practical example of where GDP requirements demand daily attention. A cold room storing vaccines must have redundant monitoring, a defined procedure for responding to alarms (including out-of-hours alarms), and a process for assessing the impact of any excursion on the affected stock. If a monitoring system goes offline for four hours on a Saturday night and nobody responds, the product integrity decision becomes much harder to defend.

Documentation, traceability, and data integrity

GDP requires records that allow full traceability of every medicinal product from supplier to customer. For each transaction, you need to record the product name, batch number, quantity, supplier, customer, and date. In the EU, wholesale distributors must be able to trace the distribution path of any product.

ALCOA+ principles (Attributable, Legible, Contemporaneous, Original, Accurate, plus Complete, Consistent, Enduring, and Available) apply to distribution records just as they do in manufacturing. Electronic warehouse management systems must have audit trails. Manual records must be signed and dated. Corrections must not obscure the original entry. These are not theoretical concerns: data integrity deficiencies appear regularly in GDP inspection findings, often related to manual temperature logs or improperly configured electronic systems that allow data deletion.

Transportation and supply chain integrity under GDP

Qualification of transport routes and conditions

Transport must be risk-assessed. The assessment considers distance, duration, seasonal temperature extremes, the number of handling points, and the product's storage requirements. Temperature-controlled shipments need validated packaging configurations. This means testing the packaging (insulated shippers, gel packs, phase-change materials) under worst-case temperature profiles to confirm the product stays within specification for the expected transit time plus a safety margin.

Where transport is outsourced, the distributor remains responsible. The contract with the logistics provider must specify GDP requirements, and the distributor must qualify the provider through audit or equivalent assessment. A common mistake is treating the logistics provider as a black box. If the carrier's vehicle breaks down and product sits on a loading dock in summer heat, the distributor owns the quality decision.

Preventing falsified medicines from entering the supply chain

GDP requires wholesale distributors to verify that their suppliers hold appropriate authorisations (manufacturing authorisation, wholesale distribution authorisation, or import authorisation) and that their customers are authorised to receive medicinal products. This supplier and customer qualification must be documented and periodically reviewed.

The EU Falsified Medicines Directive (Directive 2011/62/EU) introduced additional requirements, including safety features on packs (unique identifiers and tamper-evident devices) verified through the European Medicines Verification System. Wholesale distributors must verify the safety features of medicinal products at certain points in the supply chain. Suspect falsified medicinal products must be immediately segregated, and the competent authority must be notified.

GDP inspections and maintaining compliance

What inspectors typically assess during a GDP inspection

GDP inspections typically focus on:

• The Responsible Person's actual involvement in day-to-day operations, not just their name on the authorisation.
• Deviation and CAPA management: how deviations are identified, investigated, and closed with effective corrective and preventive actions.
• Complaint handling and recall procedures, including evidence of mock recalls.
• Self-inspection programmes: frequency, scope, and follow-up on findings.
• Qualification of outsourced activities, including transport, contract storage, and any other GDP-relevant services.
• Training records and evidence that personnel understand their GDP responsibilities.
• Temperature monitoring data, alarm management, and excursion handling.

Inspectors will review records, walk the warehouse, interview staff, and check that what your SOPs describe matches what actually happens on the floor.

Common GDP non-compliance findings

Recurring findings from GDP inspections include:

• Inadequate temperature monitoring, such as gaps in continuous monitoring data, uncalibrated sensors, or missing evidence of excursion assessments.
• Incomplete supplier or customer qualification, particularly failure to verify authorisation status before trading.
• Poor deviation management: deviations recorded but root cause investigations superficial or CAPAs not implemented.
• Insufficient training records, or training that consists of "read and sign" without demonstrated understanding.
• Responsible Person not demonstrably exercising their duties (for instance, no evidence of involvement in return-to-stock decisions).

These are not obscure findings. They appear repeatedly across competent authority inspection reports in multiple EU Member States.

Key takeaways

GDP exists to protect the integrity of medicinal products from the point of manufacturing release to the point of dispensing. The framework applies to anyone involved in the wholesale procurement, storage, transport, and supply of medicines.

Compliance rests on a functioning quality system, with a Responsible Person who has the competence, authority, and resources to exercise real oversight. Temperature control, traceability, supplier qualification, and data integrity are the operational foundations. Sustained compliance requires self-inspection, effective CAPA processes, and a willingness to address what you find rather than document and ignore it.

If you are entering a GDP-regulated role, your first steps should be to read the applicable GDP guideline in full, understand the scope of your wholesale distribution authorisation, and walk your operation with fresh eyes. The gap between what is written in SOPs and what happens on the warehouse floor is where most non-compliance lives.